About the Company
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates.
|Name||Ticker||Market Capitalization (USD M)||Revenue (USD M)||Price/Book||Price/Earning||Net Margin (%)|
|Conversion Labs Inc||CVLB||108548||35213||3.74||42.66||7.33|
|Royalty Pharma plc||RPRX||18925||2239||2.81||15.20||43.40|
|Organon & Co.||OGN||8844||7891||-4.56||5.07||22.06|
|ATAI Life Sciences N.V.||ATAI||2272||20||4.78||-10.40||-932.88|
|Cronos Group Inc||CRON||2097||57||1.32||-14.52||-258.59|
|Usana Health Sciences Inc||USNA||2079||1254||4.73||14.98||11.09|
|NRX Pharmaceuticals Inc||NRXP||1170||2321||0.45||5.05||9.91|
|Phathom Pharmaceuticals Inc||PHAT||1033||7.01||-6.45||None|
|Intersect ENT Inc||XENT||893||103||21.65||-13.01||-66.55|
|Phibro Animal Health Corp.||PAHC||893||833||3.70||16.25||6.53|
|Edgewise Therapeutics Inc||EWTX||796||2.70||-29.55||None|
|Fulcrum Therapeutics Inc||FULC||711||15||8.62||-9.63||-481.07|
|Pliant Therapeutics Inc||PLRX||614||13||2.51||-7.16||-613.56|
|Cyteir Therapeutics Inc||CYT||596||3.20||-20.62||None|
|Urovant Sciences Ltd||UROV||503||-3.65||-3.08||None|
|Ikena Oncology Inc||IKNA||404||10||2.18||-7.38||-551.28|
|Provention Bio Inc||PRVB||377||2.53||-2.94||None|
|Rain Therapeutics Inc||RAIN||355||413||2.19||-11.66||123.20|
|Verrica Pharmaceuticals Inc||VRCA||325||12||6.57||-8.92||-301.45|
|Adicet Bio Inc||ACET||280||9||1.22||-4.97||-603.06|
|Terns Pharmaceuticals Inc||TERN||252||1.40||-7.30||None|
|Milestone Pharmaceuticals Inc||MIST||219||15||1.23||-7.37||-215.93|
|Kaleido Biosciences Inc||KLDO||184||1||4.11||-2.07||None|
|Citius Pharmaceuticals Inc||CTXR||179||2.24||-7.81||None|
|Aquestive Therapeutics Inc||AQST||142||42||-2.95||-2.21||-152.73|
|Eton Pharmaceuticals Inc||ETON||124||15||6.13||-10.10||-74.52|
|Osmotica Pharmaceuticals Plc||OSMT||122||190||2.37||-1.31||-47.85|
|Kala Pharmaceuticals Inc||KALA||119||11||1.53||-0.94||None|
|Xeris Biopharma Holdings Inc||XERS||111||34||12.19||-1.44||-248.46|
|Odonate Therapeutics Inc||ODT||110||1.39||-0.94||None|
|Anebulo Pharmaceuticals Inc||ANEB||102||7.93||-2.58||None|
|Opiant Pharmaceuticals Inc||OPNT||100||37||3.03||-96.15||-3.06|
|Aerpio Pharmaceuticals Inc||ARPO||99||15||2.98||-5.24||-28.77|
|Natural Alternatives Internati||NAII||80||179||1.07||7.90||6.03|
|India Globalization Capital In||IGC||67||0||2.45||-7.60||-981.18|
|VYNE Therapeutics Inc||VYNE||51||16||0.77||2.31||-554.66|
|Assertio Holdings Inc||ASRT||36||117||0.49||-0.63||-38.05|
|Dermata Therapeutics Inc||DRMA||36||-75.67||-7.32||None|
|Acasti Pharma Inc||ACST||33||0||1.43||-1.66||-611.47|
|Nabriva Therapeutics Plc||NBRV||29||12||0.88||-0.49||-452.55|
|Lexaria Bioscience Corp||LEXX||27||1||3.76||-6.95||-445.15|
|Bio-Path Holdings Inc||BPTH||26||0||1.19||-2.49||18.96|
|Reviva Pharmaceuticals Holding||RVPH||25||1.41||-4.08||None|
|Baudax Bio Inc||BXRX||25||1||-10.80||0.76||9.10|
|Trevi Therapeutics Inc||TRVI||23||1.64||-0.66||None|
|Timber Pharmaceuticals Inc||TMBR||20||0||8.75||0.67||-527.55|
|Hoth Therapeutics Inc||HOTH||19||1.64||-2.02||None|
|Sonoma Pharmaceuticals Inc.||SNOA||11||17||3.32||-2.16||-31.96|
I nvestors in Royalty Pharma plc (Symbol: RPRX) saw new options begin trading this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2021 of $0.17 per Class A ordinary share. The dividend will be paid on ...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and ...
Investors in Royalty Pharma plc (Symbol: RPRX) saw new options begin trading today, for the December 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to ...
The US biotech stock Sage Therapeutics seems to be bouncing back while Regeneron and Royalty Pharma stocks extend losses.
Fusion Antibodies PLC is in demand after it signed a collaborative R&D agreement with a US biotechnology start-up. The company, a spin out from Queen's University Belfast which helps develop ...
Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis
Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for ...
Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis. Oxford, UK - 19 October 2021: Oxford Biom ...
Trident Royalties PLC - London-based mining royalty and streaming company - Following ... in USD143 million series B funding round in CinCor Pharma. "The proceeds from the Series B financing ...
(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.